TP53 and neoplasm: Looks good for the future of neoantigen vaccines, particularly for TP53-mutated malignancies. A tumor-specific CD3+ T cell receptor that targets the HLA-A*02:01-restricted p53R175H neoantigen; the molecular basis for this antibody’s specificity; and its ability to transform into a bispecific antibody that can lyse cancer cells when the neoantigen is present.